Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBI-1140675, a Second-Generation VMAT2 Inhibitor, in Healthy Adults
Rhea-AI Summary
Neurocrine Biosciences (NBIX) has initiated a Phase 1 clinical study of NBI-1140675, their new second-generation VMAT2 inhibitor, in healthy adults. The study will evaluate the compound's safety, tolerability, pharmacokinetics and pharmacodynamics.
NBI-1140675 is an oral, selective small molecule inhibitor designed for treating neurological and neuropsychiatric conditions. It joins NBI-1065890 as the company's second VMAT2 inhibitor in Phase 1 trials.
This development builds on Neurocrine's track record with valbenazine, their first VMAT2 inhibitor, which received FDA approval for tardive dyskinesia treatment in 2017 and for Huntington's disease chorea in 2023. Valbenazine is currently in Phase 3 trials for schizophrenia and dyskinetic cerebral palsy.
Positive
- Initiated Phase 1 trial for new VMAT2 inhibitor NBI-1140675
- Second VMAT2 inhibitor in Phase 1 trials shows pipeline expansion
- Successful track record with first VMAT2 inhibitor (2 FDA approvals)
- Two additional Phase 3 trials ongoing for valbenazine
Negative
- Early-stage development (Phase 1) indicates long path to potential approval
- No efficacy data available yet for new compound
News Market Reaction – NBIX
In the trading session that priced this news, NBIX gained 0.65%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
"We are focused on extending our bench of VMAT2 inhibitors in development, building on our successful discovery and development of valbenazine for the treatment of tardive dyskinesia and chorea in Huntington's disease," said Eiry W. Roberts, M.D., Chief Medical Officer at Neurocrine Biosciences. "NBI-1140675 is an internally discovered, highly potent, selective VMAT2 inhibitor with the potential to provide differentiated benefit in treating certain neurological and neuropsychiatric conditions."
NBI-1140675 joins NBI-1065890 as a second-generation VMAT2 inhibitor undergoing evaluation by Neurocrine in Phase 1 clinical studies. VMAT2 inhibitors have been clinically validated as effective treatments for hyperkinetic movement disorders, playing an important role in presynaptic dopamine storage and release. Neurocrine successfully developed and received
About Neurocrine Biosciences
Neurocrine Biosciences is a leading neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, endometriosis* and uterine fibroids*, as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit neurocrine.com, and follow the company on LinkedIn, X, and Facebook.
(*in collaboration with AbbVie)
NEUROCRINE, the NEUROCRINE BIOSCIENCES Logo, and YOU DESERVE BRAVE SCIENCE are registered trademarks of Neurocrine Biosciences, Inc.
Forward-Looking Statements
In addition to historical facts, this press release contains forward-looking statements that involve a number of risks and uncertainties. These statements include, but are not limited to, statements regarding the efficacy and therapeutic potential of NBI-1140675. Factors could cause actual results to differ materially from those stated or implied in the forward-looking statements include, but are not limited to, the following: risks that clinical development activities may not be initiated or completed on time or at all, or may be delayed for regulatory, manufacturing, or other reasons, may not be successful or replicate previous clinical trial results, may fail to demonstrate that our product candidates are safe and effective, or may not be predictive of real-world results or of results in subsequent clinical trials; risks that regulatory submissions for our product candidates may not occur or be submitted in a timely manner; our future financial and operating performance; risks associated with our dependence on third parties for development, manufacturing, and commercialization activities for our products and product candidates, and our ability to manage these third parties; risks that the FDA or other regulatory authorities may make adverse decisions regarding our products or product candidates; risks that the potential benefits of the agreements with our collaboration partners may never be realized; risks that our products, and/or our product candidates may be precluded from commercialization by the proprietary or regulatory rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse; risks associated with
© 2025 Neurocrine Biosciences. Inc. All Rights Reserved. CAP-NBI-US-0134 03/2025
View original content to download multimedia:https://www.prnewswire.com/news-releases/neurocrine-biosciences-announces-initiation-of-phase-1-clinical-study-evaluating-nbi-1140675-a-second-generation-vmat2-inhibitor-in-healthy-adults-302392294.html
SOURCE Neurocrine Biosciences, Inc.